Sagent and ICF Sign Development and Supply Collaboration Agreement
Posted on: Friday, 10 October 2008, 09:00 CDT
Sagent Pharmaceuticals, a privately-held specialty pharmaceutical company, and Itochu Chemical Frontier, a privately-held company in the field of pharmaceutical and organic and fine chemicals based in Japan, have signed a development and supply collaboration agreement.
Under the agreement, Itochu Chemical Frontier (ICF) will supply injectable products for which Sagent will obtain the US regulatory approval and market them in the US.
Jeffrey Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, said: "Sagent is committed to expanding its network of worldwide strategic partnerships to offer diverse and extensive pipeline of the injectable products to our hospital-focused customers and we look forward to including ICF amongst our partners."
Jun Sato, ICF's president and CEO, said: "ICF looks forward to rapidly expanding our presence in the US market. We believe that this collaboration combining ICF's experience in the Japanese market with Sagent's US focused injectable selling and marketing capabilities is an optimal path toward achieving this objective."
Source: Datamonitor
Related Articles
- Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
- Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready-to-Use IV Bags
- Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection
- Sagent Pharmaceuticals Launches Ondansetron in 5% Dextrose Injection in Premix Ready-to-Use IV Bags
- Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
- Sagent Launches Cefepime for Injection, USP
- Sagent Pharmaceuticals Launches Cefepime for Injection, USP
- Sagent Launches Cefazolin for Injection
- Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
- The Latest Head-to-Head Clinical Study Comparing the Risk of CIN Between Two Contrast Agents Used in CE-MDCT Examinations Was Published in Investigative Radiology
User Comments (0)

RSS Feeds